A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

• ClinicalTrials.gov Identifier: NCT02421939
• Recruitment Status: Active, not recruiting
• First Posted: April 21, 2015
• Results First Posted: October 17, 2019
• Last Update Posted: April 25, 2024
• Sponsor: Astellas Pharma Global Development, Inc.
• Information provided by (Responsible Party): Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )

Study Description

Brief Summary:

The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therapy as shown with overall survival (OS) compared to salvage chemotherapy, and to determine the efficacy of ASP2215 therapy as assessed by the rate of complete remission and complete remission with partial hematological recovery (CR/CRh) in these participants.

This study will also determine the overall efficacy in event-free survival (EFS) and complete remission (CR) rate of ASP2215 compared to salvage chemotherapy.

Condition or disease	Intervention/treatment	Phase
Leukemia, Acute Myeloid (AML)	Drug: gilteritinib; Drug: LoDAC (Low Dose Cytarabine); Drug: Azacitidine; Drug: MEC (Mitoxantrone, Etoposide, Cytarabine); Drug: FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)	Phase 3

Expanded Access : An investigational treatment associated with this study has been approved for sale to the public.   More info ...

Detailed Description:

Participants considered an adult according to local regulations at the time of signing informed consent may participate in this study. Participants will be randomized in a 2:1 ratio to receive ASP2215 or salvage chemotherapy. Participants will enter the screening period up to 14 days prior to the start of treatment. Prior to randomization, a salvage chemotherapy regimen will be pre-selected for each participant; options will include low-dose cytarabine (LoDAC), azacitidine, mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC), or fludarabine, cytarabine, and granulocyte colony-stimulating factor (G-CSF) with idarubicin (FLAG-IDA). The randomization will be stratified by response to first-line therapy and pre-selected salvage chemotherapy. Participants will be administered treatment over continuous 28-day cycles.

After treatment discontinuation, participants will have a pre-hematopoietic stem cell transplant (HSCT)/end-of-treatment visit within 7 days after treatment discontinuation, followed by a 30-day follow-up for safety, in which a telephone contact with the participant is sufficient unless any assessment must be repeated for resolution of treatment-related adverse events (AEs). After that, long term follow-up will be done every 3 months up to 3 years from the participant's end-of-treatment visit.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 371 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
• Actual Study Start Date: October 20, 2015
• Actual Primary Completion Date: September 17, 2018
• Estimated Study Completion Date: July 31, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Gilteritinib; Participants received 120 mg dose (3 tablets of 40 mg) orally once a day in continuous 28-day cycles, at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants met one of the treatment discontinuation criteria.	Drug: gilteritinib; tablet, oral; Other Names: ASP2215; XOSPATA®
Active Comparator: Salvage Chemotherapy; Participants received chemotherapy in 28-day cycles. Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10 days. Participants on azacitidine received 75 mg/m^2 daily by SC or IV injection for 7 days. Participants on LoDAC or azacitidine treatment continued until they met discontinuation criteria. Participants on MEC chemotherapy received mitoxantrone 8 mg/m^2 daily by IV for 5 days, etoposide 100 mg/m^2 daily by IV for 5 days and cytarabine 1000 mg/m^2 daily by IV for 5 days (days 1-5). Participants on FLAG-IDA chemotherapy received G-CSF 300 μg/m^2 daily by SC/IV for 5 days (days 1-5), fludarabine 30 mg/m^2 daily by IV for 5 days (days 2-6), cytarabine 2000 mg/m^2 daily by IV for 5 days (days 2-6) and idarubicin 10 mg/m^2 daily by IV for 3 days (days 2-4). Participants receiving MEC or FLAG-IDA received 1 cycle of therapy and were assessed for response on or after day 15.	Drug: LoDAC (Low Dose Cytarabine); subcutaneous (SC) or intravenous (IV) injection; Drug: Azacitidine; SC or IV injection; Drug: MEC (Mitoxantrone, Etoposide, Cytarabine); IV injection; Drug: FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin); SC (G-CSF) and IV (Fludarabine, Cytarabine, Idarubicin) injection

Outcome Measures

Primary Outcome Measures :

1. Duration of Overall Survival (OS) [ Time Frame: From randomization until the data cut-off date of 17 Sep 2018, median time of follow-up for OS was 17.8 months ]
   Overall survival was defined as the time from the date of randomization until the date of death from any cause (death date - randomization date + 1). For a participant who was not known to have died by the end of study follow-up, OS was censored at the date of last contact (date of last contact - randomized date + 1). The date of last contact was the latest date that the participant was known to be alive by the cutoff date. The last contact date was derived for participants alive at the analysis cutoff date. Survival rate and 95% CI were estimated using the Kaplan-Meier method and the Greenwood formula.
2. Percentage of Participants With Complete Remission and Complete Remission With Partial Hematological Recovery (CR/CRh) in the Gilteritinib Arm [ Time Frame: From randomization until the data cut-off date 04 Aug 2017, the 142 patients included in the primary analysis of CR/CRh rate were followed up at least 112 days ]
   The CR/CRh rate was defined as the number of participants who achieved either CR or CRh at any of the postbaseline visits divided by the number of participants in the analysis population.

Secondary Outcome Measures :

1. Duration of Event-Free Survival (EFS) [ Time Frame: From randomization until the data cut-off date of 17 Sep 2018, median time of follow-up for OS was 17.8 months ]
   EFS was defined as the time from the date of randomization until the date of documented relapse (excluding relapse after PR), treatment failure or death from any cause within 30 days after the last dose of study drug, whichever occurred first (earliest of [relapse date, treatment failure date, death date] - randomization date + 1). If a participant experienced relapse or death within 30 days after the last dose of study drug, the participant was defined as having an EFS event related to either "relapse" or "death", and the event date was the date of relapse or death. For a participant who was not known to have had a relapse or treatment failure or death event, EFS was censored at the date of last relapse-free disease assessment (last relapse-free disease assessment date - randomization date + 1). Data was estimated based on Kaplan-Meier estimates.
2. Percentage of Participants With Complete Remission (CR) Rate [ Time Frame: From randomization until the data cut-off date of 17 Sep 2018, all participants included in the primary analysis of CR rate were followed up at least 6 months ]
   The CR rate was defined as the number of participants who achieved the best response of CR divided by the number of participants in the analysis population.
3. Duration of Leukemia-Free Survival (LFS) [ Time Frame: From randomization until the data cut-off date of 17 Sep 2018, median time of follow-up for OS was 17.8 months ]
   The LFS was defined as the time from the date of first CRc until the date of documented relapse (excluding relapse from PR) or death for participants who achieved CRc (relapse date or death date - first CRc disease assessment date + 1). For a participant who was not known to have relapsed or died, LFS was censored on the date of last relapse-free disease assessment date (last relapse-free disease assessment date - first CRc disease assessment date + 1). For a participant who was not known to have relapsed or died, LFS was censored on the date of last relapse-free disease assessment date (last relapse-free disease assessment date - first CRc disease assessment date + 1).
4. Duration of Remission [ Time Frame: From randomization until the data cut-off date of 17 Sep 2018, median time of follow-up for OS was 17.8 months ]
   Duration of remission included duration of composite complete remission (CRc), duration of complete remission (CR)/ complete remission with partial hematologic recovery (CRh), duration of CRh, duration of CR and duration of response (CRc + partial remission (PR). The duration of response was defined as the time from the date of either first CRc or PR until the date of documented relapse (i.e., the date of first NR after CRc or PR) for participants who achieved CRc or PR (relapse date - first CRc or PR disease assessment date + 1). Participants who died without report of relapse were considered nonevents and censored at their last relapse-free disease assessment date (last relapse-free disease assessment date - first CRc or PR disease assessment date + 1). Other participants who did not relapse during the study were considered nonevents and censored at the last relapse-free assessment date. Duration of CR was only applicable to participants with best overall response of CR.
5. Percentage of Participants With Composite Complete Remission (CRc Rate) [ Time Frame: From randomization until the data cut-off date of 17 Sep 2018, median time of follow-up for OS was 17.8 months ]
   CRc rate was defined as the number of participants who achieved the best response of CRc (CR,complete remission with incomplete platelet recovery (CRp) or complete remission with incomplete hematologic recovery (CRi) divided by the number of participants in the analysis population.
6. Percentage of Participants Who Underwent Hematopoietic Stem Cell Transplant [ Time Frame: From randomization until the data cut-off date of 17 Sep 2018, median time of follow-up for OS was 17.8 months ]
   Transplantation rate is defined as the percentage of participants undergoing Hematopoietic stem cell transplant (HSCT) during the study period.
7. Change From Baseline in Brief Fatigue Inventory (BFI) [ Time Frame: Baseline and cycle 1, day 8 and cycle 2 day 1 (up to data cut off date of 17 Sep 2018) ]
   The Brief Fatigue Inventory (BFI) is a screening tool designed to assess the severity and impact of fatigue on daily functioning of participants with cancer during the 24 hours. There are 9 items on the scale. The first three questions ask participants to rate their fatigues on a scale from 0 (no fatigue) - 10 (as bad as you can imagine), with higher scores indicating worse outcome. The remaining six questions ask participants to rate how much fatigue has interfered with their daily activities on a scale from 0 (Does not interfere) to 10 (Completely interferes). A global fatigue score can be obtained by averaging all the items on the BFI. The global BFI score will be calculated only if at least 5 of the 9 items are answered. A higher BFI fatigue score indicates worse outcome.
8. Percentage of Participants With Complete Remission (CR) With Partial Hematological Recovery (CRh) [ Time Frame: From randomization until the data cut-off date of 17 Sep 2018, median time of follow-up for OS was 17.8 months ]
   CRh rate was defined as the number of participants who achieved CRh at any of the postbaseline visits and did not have a best response of CR divided by the number of participants in the analysis population.
9. Percentage of Participants Who Achieved Transfusion Conversion and Maintenance [ Time Frame: From randomization until the data cut-off date of 17 Sep 2018, median treatment duration for gilteritinib was (126.00 [4.0, 885.0]) days versus salvage chemotherapy 28.0 [5.0, 217.0] days) ]
   Transfusion conversion & maintenance rate was defined for gilteritinib arm. Participants were classified as transfusion independent if there were no RBC or platelet transfusions within 28 days prior to the first dose to 28 days after the first dose; otherwise they were classified as transfusion dependent at baseline. Participants were considered independent postbaseline if they had 1 consecutive 8 week period without any RBC or platelet transfusion from 29 days after the first dose until the last dose date. For participants who were on treatment ≤ 4 weeks or > 4 weeks but < 12 weeks and there was no RBC or platelet transfusion within postbaseline period, they were considered not evaluable; otherwise, they were considered postbaseline transfusion dependent. Transfusion conversion rate was defined for participants who had evaluable postbaseline transfusion status. Transfusion status (independent vs. dependent) at baseline and postbaseline was reported in a 2 by 2 contingency table.
10. Number of Participants With Adverse Events [ Time Frame: From first dose of study drug up to 30 days after the last dose of study drug (median treatment duration for gilteritinib was (126.00 [4.0, 885.0]) days versus salvage chemotherapy 28.0 [5.0, 217.0] days) ]
    A treatment-emergent adverse event (TEAE) was defined as an AE observed after starting administration of the study drug (gilteritinib or salvage chemotherapy). If the AE occurred on day 1 and the onset check box was marked "Onset after first dose of study drug" or the onset check box was left blank, then the AE was considered treatment emergent. If the AE occurred on day 1 and the onset check box was marked "Onset before first dose of study drug", then the AE was not considered treatment emergent. Majority of salvage chemotherapy participants finished the study by cycle 2 of treatment, the duration of exposure was longer in the gilteritinib arm compared with the salvage chemotherapy arm (126.00 [4.0, 885.0] days versus 28.0 [5.0, 217.0] days). The NCI-CTCAE is defined as National Cancer Institute-Common Terminology Criteria for Adverse Events.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Participant has a diagnosis of primary acute myeloid leukemia (AML) or AML secondary to myelodysplastic syndrome (MDS) according to WHO classification (2008) as determined by pathology review at the treating institute.

• Participant is refractory to or relapsed after first-line AML therapy (with or without hematopoietic stem cell transplant (HSCT)).

  • Refractory to first-line AML therapy is defined as:

    1. Participant did not achieve complete remission/complete remission with incomplete hematologic recovery/complete remission with incomplete platelet recovery (CR/CRi/CRp) under initial therapy. A Participant eligible for standard therapy must receive at least one cycle of an anthracycline containing induction block in standard dose for the selected induction regimen. A Participant not eligible for standard therapy must have received at least one complete block of induction therapy seen as the optimum choice of therapy to induce remission for this subject.

  • Untreated first hematologic relapse is defined as:

    1. Participant must have achieved a CR/CRi/CRp (criteria as defined by [Cheson et al, 2003], see Section 5.3) with first line treatment and has hematologic relapse.
• Participant is positive for FLT3 mutation in bone marrow or whole blood as determined by the central lab. A Participant with rapidly proliferative disease and unable to wait for the central lab results can be enrolled based on a local test performed after completion of the last interventional treatment. Participants can be enrolled from a local test result if they have any of the following FLT3 mutations: FLT3 internal tandem duplication (ITD), FLT3 tyrosine kinase domain (TKD)/D835 or FLT3- TKD/I836.
• Participant has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
• Participant is eligible for pre-selected salvage chemotherapy.

• Participant must meet the following criteria as indicated on the clinical laboratory tests:

  • Serum aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x upper limit of normal (ULN)
  • Serum total bilirubin ≤ 1.5 x ULN
  • Serum creatinine ≤ 1.5 x ULN or an estimated glomerular filtration rate of > 50 mL/min as calculated by the Modification of Diet in Renal Disease equation.
• Participant is suitable for oral administration of study drug.

• Female Participant must either:

  • Be of non-child bearing potential:

    1. post-menopausal (defined as at least 1 year without any menses) prior to Screening, or
    2. documented as surgically sterile (at least 1 month prior to Screening)

  • Or, if of childbearing potential,

    1. Agree not to try to become pregnant during the study and for 180 days after the final study administration
    2. And have a negative urine pregnancy test at Screening
    3. And, if heterosexually active, agree to consistently use highly effective contraception per locally accepted standards in addition to a barrier method starting at Screening and throughout the study period and for 180 days after the final study drug administration.
• Female Participant must agree not to breastfeed at Screening and throughout the study period and for 60 days after the final study drug administration.
• Female Participant must not donate ova starting at Screening and throughout the study period and for 180 days after the final study drug administration.
• Male Participant and their female partners who are of childbearing potential must be using highly effective contraception per locally accepted standards in addition to a barrier method starting at Screening and continue throughout the study period and for 120 days after the final study drug administration.
• Male Participant must not donate sperm starting at Screening and throughout the study period and 120 days after the final study drug administration.
• Participant agrees not to participate in another interventional study while on treatment.

Exclusion Criteria:

• Participant was diagnosed as acute promyelocytic leukemia (APL).
• Participant has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
• Participant has AML secondary to prior chemotherapy for other neoplasms (except for MDS).
• Participant is in second or later hematologic relapse or has received salvage therapy for refractory disease
• Participant has clinically active central nervous system leukemia.
• Participant has been diagnosed with another malignancy, unless disease-free for at least 5 years. Participants with treated nonmelanoma skin cancer, in situ carcinoma or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed. Participants with organ-confined prostate cancer with no evidence of recurrent or progressive disease are eligible if hormonal therapy has been initiated or the malignancy has been surgically removed or treated with definitive radiotherapy.
• Participant has received prior treatment with ASP2215 or other FLT3 inhibitors (with the exception of sorafenib and midostaurin used in first-line therapy regimen as part of induction, consolidation, and/or maintenance).
• Participant has clinically significant abnormality of coagulation profile, such as disseminated intravascular coagulation (DIC).
• Participant has had major surgery within 4 weeks prior to the first study dose.
• Participant has radiation therapy within 4 weeks prior to the first study dose.
• Participant has congestive heart failure New York Heart Association (NYHA) class 3 or 4, or Participant with a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram performed within 3 months prior to study entry results in a left ventricular ejection fraction that is ≥ 45%.
• Participant requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A.
• Participants with mean of triplicate Fridericia-corrected QT interval (QTcF) > 450 ms at Screening based on central reading.
• Participants with Long QT Syndrome at Screening.
• Participants with hypokalemia and hypomagnesemia at Screening (defined as values below lower limit of normal [LLN]).
• Participant requires treatment with concomitant drugs that are strong inhibitors or inducers of P glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
• Participant requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.
• Participant has an active uncontrolled infection.
• Participant is known to have human immunodeficiency virus infection.
• Participant has active hepatitis B or C, or other active hepatic disorder.
• Participant has any condition which makes the Participant unsuitable for study participation.
• Participant has active clinically significant GVHD or is on treatment with systemic corticosteroids for GVHD.
• Participant has an FLT3 mutation other than the following: FLT3-ITD, FLT3-TKD/D835 or FLT3-TKD/I836.

Contacts and Locations

Locations

United States, Alabama

Site US10011

Birmingham, Alabama, United States, 35294-0006

United States, California

Site US10012

Los Angeles, California, United States, 90095-1752

Site US10076

Orange, California, United States, 92868

Site US10073

San Francisco, California, United States, 94143

United States, Connecticut

Site US10067

New Haven, Connecticut, United States, 06504

United States, Florida

Site US10045

Gainesville, Florida, United States, 32610

United States, Georgia

Site US10081

Atlanta, Georgia, United States, 30342

United States, Illinois

Site US10006

Chicago, Illinois, United States, 60637

United States, Kansas

Site US10075

Westwood, Kansas, United States, 66205

United States, Kentucky

Site US10074

Louisville, Kentucky, United States, 40202

United States, Louisiana

Site US10048

New Orleans, Louisiana, United States, 70112

United States, Maryland

Site US10005

Baltimore, Maryland, United States, 21201

United States, Massachusetts

Site US10034

Boston, Massachusetts, United States, 02114

Site US10022

Boston, Massachusetts, United States, 02215

Site US10085

Boston, Massachusetts, United States, 02215

United States, Michigan

Site US10087

Detroit, Michigan, United States, 48201

United States, Minnesota

Site US10057

Minneapolis, Minnesota, United States, 55455

United States, New Hampshire

Site US10023

Lebanon, New Hampshire, United States, 03756-1000

United States, New Jersey

Site US10027

Hackensack, New Jersey, United States, 07601

Site US10077

New Brunswick, New Jersey, United States, 08903

United States, New York

Site US10001

Buffalo, New York, United States, 14263

Site US10037

New York, New York, United States, 10029

Site US10008

New York, New York, United States, 10032

Site US10013

New York, New York, United States, 10065

Site US10072

New York, New York, United States, 10065

Site US10046

Syracuse, New York, United States, 13210

United States, North Carolina

Site US10024

Durham, North Carolina, United States, 27710

Site US10078

Winston-Salem, North Carolina, United States, 27157

United States, Ohio

Site US10044

Cleveland, Ohio, United States, 44106

Site US10084

Columbus, Ohio, United States, 43210

United States, Oklahoma

Site US10058

Oklahoma City, Oklahoma, United States, 73104

United States, Pennsylvania

Site US10041

Hershey, Pennsylvania, United States, 17033

Site US10010

Philadelphia, Pennsylvania, United States, 19104

Site US10080

Philadelphia, Pennsylvania, United States, 19107

United States, South Carolina

Site US10014

Charleston, South Carolina, United States, 29425

United States, Tennessee

Site US10063

Nashville, Tennessee, United States, 37232-0656

United States, Wisconsin

Site US10035

Milwaukee, Wisconsin, United States, 53226

Belgium

Site BE32002

Yvoir, Belgium, 5530

Canada, Alberta

Site CA15004

Edmonton, Alberta, Canada, T6G 2G3

Canada, Ontario

Site CA15001

Hamilton, Ontario, Canada, L8V 1C3

Site CA15015

Toronto, Ontario, Canada, M5G 2M9

Canada, Quebec

Site CA15003

Montreal, Quebec, Canada, H1T 2M4

France

Site FR33013

Brest, France, 29609

Site FR33002

Le Chesnay Cedex, France, 78157

Site FR33010

Lille, France, 59037

Site FR33009

Pessac, France, 33604

Site FR33014

Rennes, France, 35033

Site FR33008

Toulouse, France, 31059

Germany

Site DE49009

Dresden, Germany, 01307

Site DE49011

Leipzig, Germany, 04103

Site DE49003

Marburg, Germany, 35043

Site DE49002

Munchen, Germany, 81737

Site DE49010

Tubingen, Germany, 72076

Israel

Site IL97201

Ashkelon, Israel, 78278

Site IL97209

Haifa, Israel, 31096

Site IL97203

Jerusalem, Israel, 91031

Site IL97210

Jerusalem, Israel, 91120

Site IL97206

Petah Tikva, Israel, 49100

Site IL97208

Rehovot, Israel, 76100

Italy

Site IT39005

Bologna, Italy, 40138

Site IT39010

Brescia, Italy, 25126

Site IT39001

Milan, Italy, 20132

Site IT39004

Palermo, Italy, 90146

Site IT39011

Pavia, Italy, 27100

Site IT39007

Roma, Italy, 00189

Site IT39002

Varese, Italy, 21100

Japan

Site JP81002

Nagoya, Aichi, Japan

Site JP81010

Narita, Chiba, Japan

Site JP81026

Yoshida-gun, Fukui, Japan

Site JP81016

Sapporo, Hokkaido, Japan

Site JP81018

Kobe, Hyogo, Japan

Site JP81017

Tsukuba, Ibaraki, Japan

Site JP81009

Isehara, Kanagawa, Japan

Site JP81006

Yokohama, Kanagawa, Japan

Site JP81012

Sendai, Miyagi, Japan

Site JP81007

Kurashiki, Okayama, Japan

Site JP81014

Osakasayama, Osaka, Japan

Site JP81020

Kawagoe, Saitama, Japan

Site JP81027

Shimotsuke, Tochigi, Japan

Site JP81005

Chuo-ku, Tokyo, Japan

Site JP81004

Shinagawa-ku, Tokyo, Japan

Site JP81022

Shinjuku-ku, Tokyo, Japan

Site JP81023

Akita, Japan

Site JP81021

Aomori, Japan

Site JP81013

Kumamoto, Japan

Site JP81025

Kyoto, Japan

Site JP81008

Nagasaki, Japan

Site JP81024

Okayama, Japan

Site JP81011

Osaka, Japan

Korea, Republic of

Site KR82005

Suwon-si, Gyeonggi-do, Korea, Republic of, 443380

Site KR82010

Busan, Korea, Republic of, 602739

Site KR82009

Goyang, Korea, Republic of, 602-715

Site KR82003

Jeollanam-do, Korea, Republic of, 519-809

Site KR82007

Seoul, Korea, Republic of, 110-744

Site KR82004

Seoul, Korea, Republic of, 120-752

Site KR82001

Seoul, Korea, Republic of, 135710

Site KR82002

Seoul, Korea, Republic of, 137701

Site KR82008

Seoul, Korea, Republic of, 138-736

Site KR82011

Seoul, Korea, Republic of, 156-707

Poland

Site PL48002

Gdansk, Poland, 80-952

Site PL48005

Opole, Poland, 45-372

Site PL48004

Wroclaw, Poland, 50-367

Spain

Site ES34009

Badalona, Spain, 08025

Site ES34011

Barcelona, Spain, 08035

Site ES34012

Barcelona, Spain, 08036

Site ES34010

Barcelona, Spain, 08916

Site ES34016

Girona, Spain, 17007

Site ES34005

L'Hospitalet de Llobregat, Spain, 08907

Site ES34014

Salamanca, Spain, 37007

Site ES34017

Valencia, Spain, 46026

Taiwan

Site TW88606

Kaohsiung, Taiwan, 112

Site TW88604

Kaohsiung, Taiwan, 83301

Site TW88609

Taichung City, Taiwan, 40705

Site TW88608

Taichung, Taiwan, 404

Site TW88601

Tainan, Taiwan, 704

Site TW88603

Taipei, Taiwan, 10002

Site TW88610

Taipei, Taiwan, 10449

Site TW88611

Taipei, Taiwan, 112

Site TW88602

Taipei, Taiwan, 114

Site TW88605

Taoyuan, Taiwan, 33305

Turkey

Site TR90001

Ankara, Turkey, 06100

Site TR90004

Ankara, Turkey, 06500

United Kingdom

Site GB44014

Bournemouth, United Kingdom, BH7 7DW

Site GB44013

Harrow, United Kingdom, HA1 3UJ

Site GB44003

Manchester, United Kingdom, M13 9WL

Site GB44015

Plymouth, United Kingdom, PL6 8DH

Sponsors and Collaborators

Astellas Pharma Global Development, Inc.

Investigators

• Study Director: Executive Medical Director; Astellas Pharma Global Development, Inc.

  Study Documents (Full-Text)

Documents provided by Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. ):

Study Protocol  [PDF] May 16, 2018

Statistical Analysis Plan  [PDF] September 27, 2018

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022 Apr 12;6(7):2144-2155. doi: 10.1182/bloodadvances.2021006489.

Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022 Jun 9;139(23):3366-3375. doi: 10.1182/blood.2021011583.

Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688. Erratum In: N Engl J Med. 2022 May 12;386(19):1868.

• Responsible Party: Astellas Pharma Global Development, Inc.
• ClinicalTrials.gov Identifier: NCT02421939
• Other Study ID Numbers: 2215-CL-0301; 2015-000140-42 ( EudraCT Number )
• First Posted: April 21, 2015
• Results First Posted: October 17, 2019
• Last Update Posted: April 25, 2024
• Last Verified: April 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP); Clinical Study Report (CSR)
• Time Frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
• Access Criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
• URL: https://www.clinicalstudydatarequest.com/

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. ):

ASP2215; Relapsed Acute Myeloid Leukemia; FLT3 Mutation; gilteritinib; Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia (AML); XOSPATA®

Additional relevant MeSH terms:

Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Cytarabine; Fludarabine; Etoposide; Azacitidine; Mitoxantrone; Idarubicin; Lenograstim; Gilteritinib; Antineoplastic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Enzyme Inhibitors; Antiviral Agents; Anti-Infective Agents; Analgesics; Sensory System Agents; Peripheral Nervous System Agents